Literature DB >> 12356422

Effect of 5-fluorouracil on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats.

Qingyu Zhou1, Eli Chan.   

Abstract

The interaction between the antineoplastic agent 5-fluorouracil (5-FU) and the oral anticoagulant warfarin enantiomers was investigated in rats. An increase in hypoprothrombinaemic response, assessed by means of percent changes of prothrombin complex activity and clotting factor VII activity, to warfarin, was observed following oral administration of 1.5 mg/kg racemic warfarin to rats during a 8-day intraperitoneal dose regimen of 5-FU (13.3 mg/kg daily). 5-FU had no apparent effect on the baseline blood coagulation, the in vitro rat serum protein binding as well as the absorption and distribution of the S- and R-enantiomers of warfarin in rats. Yet treatment with 5-FU produced a significant decrease in the total serum clearance value of S-warfarin in rats. The decreased total clearance was attributed mainly to a significant decrease in the formation rate of the overall oxidative metabolites of the more potent S-enantiomer of warfarin. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12356422     DOI: 10.1016/s0928-0987(02)00148-3

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  3 in total

1.  Adverse Interaction between Capecitabine and Warfarin Resulting in Altered Coagulation Parameters: A Review of the Literature Starting from a Case Report.

Authors:  Giovanni Giunta
Journal:  Case Rep Med       Date:  2010-07-06

2.  Effects of etravirine on the pharmacokinetics and pharmacodynamics of warfarin in rats.

Authors:  J John; M John; L Wu; C Hsiao; C V Abobo; D Liang
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

3.  Inhibitory effect of 5-fluorouracil on human cytochrome P(450) isoforms in human liver microsomes.

Authors:  Ji-Young Park; Kyoung-Ah Kim
Journal:  Eur J Clin Pharmacol       Date:  2003-08-05       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.